Neurocrine Biosciences (NBIX) EBITDA (2010 - 2026)

Neurocrine Biosciences has reported EBITDA for 17 years, with the latest figure at $185.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 1568.47% year-over-year to $185.2 million; the trailing twelve-month figure through Mar 2026 stood at $660.0 million (up 111.88% YoY), and the FY2025 full-year result was $485.9 million, up 42.87% from the prior year.
• EBITDA for Q1 2026 stood at $185.2 million, up from $153.6 million in the prior quarter.
• The five-year high for EBITDA was $210.2 million in Q3 2025, with the low at -$71.4 million in Q1 2023.
• Historically, EBITDA has averaged $83.8 million across 5 years, with a median of $94.4 million in 2024.
• Annual changes were most pronounced in 2023 — EBITDA plunged 1233.33% — and 2026, when it surged 1568.47%.
• Neurocrine Biosciences' EBITDA stood at $95.1 million in 2022, then soared by 64.46% to $156.4 million in 2023, then slumped by 39.64% to $94.4 million in 2024, then soared by 62.71% to $153.6 million in 2025, then rose by 20.57% to $185.2 million in 2026.
• The last three EBITDA figures came in at $185.2 million (Q1 2026), $153.6 million (Q4 2025), and $210.2 million (Q3 2025), per Business Quant data.